Zentalis Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Zentalis PharmaceuticalsDer Gewinn des Unternehmens wird voraussichtlich um 3% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 34.1% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 5.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -128.4% betragen.

Wichtige Informationen

-3.0%

Wachstumsrate der Gewinne

5.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	34.1%
Zukünftige Eigenkapitalrendite	-128.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

May 09

Recent updates

Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher

Jun 19

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Jun 13

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

May 09

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

Apr 12

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Feb 29

Zentalis: Leading WEE1 Developer After AstraZeneca's Exit

Feb 05

Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

Jan 09

We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

Oct 13

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Jun 30

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Mar 17

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Dec 01

Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer

Sep 27

Zentalis Pharmaceuticals has a new chief medical officer

Sep 19

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Aug 17

Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

May 02

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Jan 12

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Oct 14

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jul 02

Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Mar 08

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jan 20

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:ZNTL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	20	-297	-305	-268	9
12/31/2025	N/A	-286	-273	-233	9
12/31/2024	41	-212	-204	-189	11
6/30/2024	41	-195	-167	-166	N/A
3/31/2024	41	-219	-211	-211	N/A
12/31/2023	N/A	-292	-208	-208	N/A
9/30/2023	N/A	-286	-205	-205	N/A
6/30/2023	N/A	-285	-201	-199	N/A
3/31/2023	N/A	-241	-165	-163	N/A
12/31/2022	N/A	-237	-166	-164	N/A
9/30/2022	N/A	-232	-168	-163	N/A
6/30/2022	N/A	-182	-169	-164	N/A
3/31/2022	N/A	-168	-173	-167	N/A
12/31/2021	N/A	-159	-160	-154	N/A
9/30/2021	N/A	-149	-149	-144	N/A
6/30/2021	N/A	-179	-133	-132	N/A
3/31/2021	N/A	-152	-109	-107	N/A
12/31/2020	N/A	-118	-88	-87	N/A
9/30/2020	N/A	-92	-73	-73	N/A
6/30/2020	N/A	-70	-62	-62	N/A
3/31/2020	N/A	-53	-47	-47	N/A
12/31/2019	N/A	-46	-39	-39	N/A
12/31/2018	0	-23	-24	-24	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ZNTL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ZNTL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ZNTL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ZNTLDie Einnahmen des Unternehmens (43.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ZNTLDie Einnahmen des Unternehmens (43.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ZNTL wird voraussichtlich in 3 Jahren unrentabel sein.

Zentalis Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 8.9% to US$32.44

Consensus revenue estimates increase by 315%

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

Price target decreased by 21% to US$39.10

Price target increased by 11% to US$51.78

Price target decreased by 12% to US$45.90

Recent updates

Zentalis Pharmaceuticals, Inc. Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Broker Revenue Forecasts For Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Are Surging Higher

Zentalis Pharmaceuticals, Inc. Provides Update on Azenosertib Clinical Development Program

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Zentalis Pharmaceuticals Announces Appointment of Luke Walker, M.D., to Board of Directors

Now 24% overvalued

Zentalis Pharmaceuticals, Inc. to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

Price target decreased by 8.9% to US$32.44

Consensus revenue estimates increase by 315%

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

Now 21% overvalued after recent price rise

Zentalis Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2024

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024

Zentalis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Zentalis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Zentalis: Leading WEE1 Developer After AstraZeneca's Exit

Co-Founder notifies of intention to sell stock

Zentalis Pharmaceuticals, Inc. Announces Executive Changes

Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

Independent Chairman of the Board recently bought US$168k worth of stock

Zentalis Pharmaceuticals, Inc. Announces Executive Changes

Price target decreased by 21% to US$39.10

New minor risk - Share price stability

We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

Chief Medical Officer notifies of intention to sell stock

Zentalis Pharmaceuticals, Inc. Appoints Kimberly Freeman as Chief Strategy Officer

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell Small Cap Comp Value Index

Zentalis Pharmaceuticals, Inc. Announces Potential for Azenosertib (Zn-C3) to Address Large Unmet Need Across an Array of Cancers

Price target increased by 11% to US$51.78

Co-Founder notifies of intention to sell stock

High number of new directors

Zentalis Announces Presentation of Positive Phase 1B Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy

Price target decreased by 12% to US$45.90

Zentalis Pharmaceuticals, Inc. Appoints Diana Hausman to the Board of Directors

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Zentalis Pharmaceuticals, Inc. Appoints Iris Roth as Chief Operating Officer

Co-Founder notifies of intention to sell stock

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Less than half of directors are independent

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

Zentalis Pharmaceuticals, Inc. Promotes Co-Founder Kevin Bunker to Chief Scientific Officer

Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer

Zentalis Pharmaceuticals, Inc. Appoints Carrie Brownstein as Chief Medical Officer

Co-Founder notifies of intention to sell stock

Zentalis Pharmaceuticals has a new chief medical officer

Zentalis Pharmaceuticals, Inc Appoints Dr. Jan Skvarka to Its Board of Directors

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$72.50

Chief Operating Officer notifies of intention to sell stock

Zentalis Pharmaceuticals, Inc. Announces Resignation of Alexis M. Pinto as Chief Legal Officer and Secretary of the Company, Effective July 5, 2022

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

Less than half of directors are independent

Zentalis Pharmaceuticals, Inc. Announces Management Changes

Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

Price target decreased to US$85.70

Zentalis Pharmaceuticals, Inc. Announces the Interim Data from the Ongoing Phase 1/2 Clinical Trial Evaluating Zn-c3 as a Monotherapy for the Treatment of Advanced Solid Tumors

Price target decreased to US$90.80

CFO & Treasurer notifies of intention to sell stock

Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-C3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR

Chief Operating Officer notifies of intention to sell stock

President notifies of intention to sell stock

Insider exercised options and sold US$1.3m worth of stock

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Chief Operating Officer recently sold US$781k worth of stock